• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Luke Maese, DO

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
0 out of 5 Patient Rating

Languages Spoken: English

Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trials in pediatric acute lymphoblastic leukemia. He serves as a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trials in pediatric acute lymphoblastic leukemia. He serves as a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

Clinical Locations

Primary Children's Hospital
Pediatric Hematology/Oncology

801-662-4700

100 N Mario Capecchi Drive
Salt Lake City, UT  84113

Specialties

  • Genetic Counselor
  • Pediatric Hematology & Oncology

Board Certification and Academic Information

Academic Departments Pediatrics - Associate Professor (Clinical)
Academic Divisions Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trials in pediatric acute lymphoblastic leukemia. He serves as a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trials in pediatric acute lymphoblastic leukemia. He serves as a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

Academic Locations

Board Certification and Academic Information

Academic Departments Pediatrics - Associate Professor (Clinical)
Academic Divisions Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Education History

Fellowship University of Utah
Pediatric Hematology/Oncology
Fellow, 2015
Residency Children’s Hospital of Pittsburgh of UPMC
Pediatrics
Resident, 2012
Professional Medical Kansas City University of Medicine and Biosciences
Osteopathic Medicine
D.O., 2009
Undergraduate University of Kansas
Human Biology
B.G.S., 2004

Selected Publications - Journal Articles

Journal Article

  1. Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E (2022). Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG). Neuro Oncol.
  2. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clin Neurol Neurosurg, 212, 107064.
  3. Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J (2021). Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol, 5.
  4. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC (2021). Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol.
  5. Iglesias Cardenas F, Agarwal AM, Vagher J, Maese L, Fluchel M, Afify Z (2020). Two Clonally Distinct B-Cell Lymphomas Reveal the Diagnosis of XLP1 in a Male Child and His Asymptomatic Male Relatives: Case Report and Review of the Literature. J Pediatr Hematol Oncol, 43(8), e1210-e1213.
  6. Maese L, Rizzari C, Coleman R, Power A, van der Sluis I, Rau RE (2021). Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? Pediatr Blood Cancer, 68(10), e29169.
  7. Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman JD (2022). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol, 7(10), 1521-1528.
  8. Bender C, Maese L, Carter-Febres M, Verma A (2021). Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood Lymphat Cancer, 11, 25-40.
  9. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance JE (2020). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. J Adolesc Young Adult Oncol, 10(2), 175-184.
  10. Lozano-Chinga M, Draper L, George TI, Agarwal AM, Dansie DM, Maese L (2020). Bone marrow necrosis in pediatric malignancies: 10-Year retrospective review and review of literature. Pediatr Blood Cancer, 68(3), e28806.
  11. Olson J, Mehra S, Hersh AL, Thorell EA, Stoddard GJ, Maese L, Barnette PE, Lemons RS, Pavia AT, Knackstedt ED (2019). Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. J Pediatric Infect Dis Soc, 10(1), 27-33.
  12. Kim J, Light N, Subasri V, Young EL, Wegman-Ostrosky T, Barkauskas DA, Hall D, Lupo PJ, Patidar R, Maese LD, Jones K, Wang M, Tavtigian SV, Wu D, Shlien A, Telfer F, Goldenberg A, Skapek SX, Wei JS, Wen X, Catchpoole D, Hawkins DS, Schiffman JD, Khan J, Malkin D, Stewart DR (2021). Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precis Oncol, 5.
  13. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz E (2020). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, Online ahead of print, 178-186.
  14. Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, Lloyd S, Kokeny KE, Hitchcock YJ, Poppe MM, Gaffney DK, Tao R (2020). Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study. Cancer Med, 9(21), 7954-7963.
  15. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba N (2020). Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(1), 81-112.
  16. Maese L, Raetz EA (2019). Can Ph-like ALL be effectively targeted? Best Pract Res Clin Haematol, 32(4), 101096.
  17. Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols KE (2019). Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia? J Clin Oncol, 37(24), 2098-2104.
  18. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman JD (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatr Blood Cancer, 66(5), e27629.
  19. Maese L, Tasian SK, Raetz EA (2017). How is the Ph-like signature being incorporated into ALL therapy? Best Pract Res Clin Haematol, 30(3), 222-228.
  20. Maese L, Li KD, Xu X, Afify Z, Paxton CN, Putnam A (2017). Acute Leukemia and Concurrent Mediastinal Germ Cell Tumor: Case Report and Literature Review. Fetal Pediatr Pathol, 36(2), 168-176.
  21. Andrade D, Velinder M, Singer J, Maese L, Bareyan D, Nguyen H, Chandrasekharan MB, Lucente H, McClellan D, Jones D, Sharma S, Liu F, Engel ME (2016). SUMOylation Regulates Growth Factor Independence 1 in Transcriptional Control and Hematopoiesis. Mol Cell Biol, 36(10), 1438-50.

Case Report

  1. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clin Neurol Neurosurg, 212, 107064.
  2. Thomsen W, Maese L, Vagher J, Moore K, Cheshier SH, Hofmann JW, Bruggers C (2022). Early Presentation of Homozygous Mismatch Repair Deficient Glioblastoma in Teen With Lynch Syndrome: Implications for Treatment and Surveillance. JCO Precis Oncol, 5, 670-675.
  3. Donovan LN, Kohlmann W, Snow AK, Neklason DW, Schiffman JD, Maese L (2020). Germ Cell Mosaicism: A Rare Cause of Li-Fraumeni Recurrence Among Siblings. JCO Precis Oncol, 4.

Editorial

  1. Maese L, Schiffman JD (2018). The evidence for expanded genetic testing for pediatric patients with cancer. Future Oncol, 14(3), 187-190.

Other

  1. Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J (2021). Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol (5). United States.

Huntsman Cancer Institute News

Research Identifies Genomic Markers of Aggressive Childhood Leukemias

Site Links

  • Find an Interpreter
  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • Referring Providers

Helpful Links

  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Surprise Billing Rights
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

801-581-2121

  • Facebook
  • Twitter
  • Youtube
  • Instagram

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2022 University of Utah Health